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Abstract
There is evidence that suggests a reciprocal functional link between the serotonergic and the somatostatinergic system in the rat
 .frontoparietal cortex. However, to date, the role of endogenous 5-hydroxytryptamine serotonin on the regulation of the somatostatin
 .  .  .SS receptor–adenylyl cyclase AC system remains unclear. In the present study, the administration of fluoxetine 10 mgrkg i.p. , a
w125 x 115-hydroxytryptamine uptake inhibitor in a single dose or administered daily for 14 days increased the number of specific I Tyr -SS
receptors, with no change in the receptor affinity, in rat frontoparietal cortical membranes. However, the capacity of SS to inhibit
 .forskolin FK -stimulated AC activity in these membranes was lower than in the control groups. The ability of the stable GTP analogue
X   . .5 -guanylylimidodiphosphate Gpp NH p to inhibit FK-stimulated AC activity in frontoparietal cortical membranes was also decreased in
 .rats acutely and chronically treated with fluoxetine. p-Chloroamphetamine 5 mgrkg i.p. , which leads to a lasting reduction of
5-hydroxytryptamine innervation, administered on days 1, 3 and 5 and the rats sacrificed 1 or 3 weeks after the first injection, decreased
the number of SS receptors without changing the receptor affinity. In this experimental group, SS also caused a significantly lower
 .inhibition of FK-stimulated AC activity. p-Chloroamphetamine had no effect on the ability of Gpp NH p to inhibit FK-stimulated AC
activity in frontoparietal cortical membranes at all the time periods studied. The present results suggest that under normal circumstances
some SS receptors are under a tonic stimulatory control through the serotonergic system. q 1997 Elsevier Science B.V.
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1. Introduction
There is evidence that suggests a reciprocal functional
link between the serotonergic and the somatostatinergic
system in the rat frontoparietal cortex. This cerebral area is
 . w xrich in somatostatin SS -containing neurons 36 and SS
w xreceptors 8 and receives a dense serotonergic innervation
w x 22 . In the brain, both SS and 5-hydroxytryptamine sero-
.tonin have been implicated in motor and sensory func-
w xtions 10,18,22,40 . SS mediates its various functions
through receptors that are coupled to GTP-binding proteins
 . w xG-proteins 34,46 , inducing inhibition of adenylyl cy-
 . w x w xclase AC 6,7,46 , reduction in calcium currents 54 and
w xincreases in potassium channel conductance 53 . In the rat
cerebral cortex, both 5-hydroxytryptamine 5-HT and 5-1
w xHT receptors have been described 11 , with an apparent2
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prevalence of the latter class. The binding capacity of
5-hydroxytryptamine 5-HT receptors was significantly in-1
creased in the cerebral cortex of rats treated for 10 days
with SS, whereas the affinity of 5-hydroxytryptamine 5-
w xHT receptors was significantly decreased 37 . Recently,1
serotonergic axon terminals have been demonstrated to be
present on SS-immunoreactive neurons of the rat paraven-
w xtricular nucleus 26 . Recent studies have also shown that
selective serotonergic lesions in rats increase preproso-
w xmatostatin mRNA expression in the striatum 2 . In addi-
tion, long-term treatment with 5-hydroxytryptamine uptake
inhibitors, such as clomipramine and zimelidine, or with a
5-hydroxytryptamine precursor reduces cerebral SS-like
w ximmunoreactivity content 24 . On the other hand, SS
w xfacilitates 5-hydroxytryptamine release 52 and stimulates
w xboth its synthesis and utilization 13 . Alterations of the
somatostatinergic and serotonergic systems have been as-
sociated with depression, Alzheimer’s disease, schizophre-
0169-328Xr97r$17.00 q 1997 Elsevier Science B.V. All rights reserved.
 .PII S0169-328X 97 00038-7
( )G. Munoz-Acedo et al.rMolecular Brain Research 47 1997 117–124˜118
w xnia and Huntington’s chorea 23,42 . To clarify the possi-
ble role of endogenous 5-hydroxytryptamine on the regula-
tion of the SS receptor–AC system in the rat brain, we
examined the effect of the enhancement of serotonergic
neurotransmission by increasing 5-hydroxytryptamine
availability in the vicinity of the receptor site with fluoxe-
  .tine 3- p-trifluoromethylphenoxy -N-methyl-3-phenylpro-
.pylamine hydrochloride , a highly selective 5-hydroxytryp-
w xtamine re-uptake inhibitor 55 . The selectivity and potency
of this drug as an inhibitor of the 5-hydroxytryptamine
re-uptake pump has aroused considerable interest and is
being widely used as a tool for studying the functional role
of the serotonergic system and for the treatment of mental
w xdepression 50 . In addition, we studied the effects of a
decrease in serotonergic neurotransmission by reduction of
5-hydroxytryptamine innervation in the neocortex with the
w xamphetamine derivate p-chloroamphetamine 12 . There-
fore, the present study assessed the acute and chronic
effect of fluoxetine and p-chloroamphetamine on the spe-
cific binding of SS to its receptors, the ability of SS to
 .inhibit forskolin FK -stimulated AC activity and the func-
tional activity of guanine nucleotide-binding inhibitory
 .proteins G -proteins in rat frontoparietal cortical mem-i
branes.
2. Materials and methods
2.1. Materials
Synthetic Tyr11-SS was purchased from Universal Bio-
 . 125 logicals Cambridge, UK ; carrier-free Na I IMS 300,
.100 mCirml was purchased from the Radiochemical Cen-
 .ter Amersham, UK ; fluoxetine, p-chloroamphetamine,
bacitracin, phenylmethylsulphonyl fluoride, guanosine
 . Xtriphosphate GTP , 5 -guanylylimidodiphosphate
  . .Gpp NH p ; 3-isobutyl-1-methylxanthine and bovine
serum albumin were purchased from Sigma St. Louis,
.MO, USA . All other reagents were of the highest purity
commercially available.
2.2. Experimental animals
The animal experiments performed in the present study
were conducted under the guidelines of the Animal Care
Committee of Alcala University and the experimental pro-´
tocols have been approved. Wistar rats weighing 200–250
g at the beginning of the treatment were used in all
experiments. The rats were housed in groups of five under
 .controlled room temperature 228C , in a constant 12-h
light–dark cycle, with food and water given ad libitum.
Fluoxetine and p-chloroamphetamine dissolved in saline
were injected i.p. in a volume of 2 mlrkg. In the acute
treatment, a single fluoxetine dose of 10 mgrkg i.p. was
w xinjected as previously described 55 . In the chronic treat-
ment, fluoxetine was injected at a dose of 10 mgrkg i.p.
once daily for 14 days. Animals were sacrificed by decapi-
tation 24 h after the last injection as previously described
w x47 . The fluoxetine dose of 10 mgrkg i.p. was observed
w xby Wong et al. 55 to alter the response of rat forebrain
neurons to 5-hydroxytryptamine. p-Chloroamphetamine
w xtreatment was carried out as previously described 51
according to the following schemes: a dose of 5 mgrkg of
p-chloroamphetamine was administered on days 1, 3 and 5
and the rats were decapitated at 1 or 3 weeks after the first
injection. Control animals for each group were injected
with saline at identical intervals. The brain was rapidly
removed and the frontoparietal cortex was dissected over
w xice according to the method of Glowinski and Iversen 16 .
2.3. Measurement of 5-hydroxytryptamine
To assess the destruction of serotonergic neurons in
p-chloroamphetamine-treated rats, frontoparietal cortical
5-hydroxytryptamine levels in control and treated rats were
measured by high-performance liquid chromatography
 . w xHPLC with electrochemical detection 48 .
2.4. Binding assay
Tyr11-SS was radioiodinated by chloramine-T iodina-
w xtion according to the method of Greenwood et al. 17 . The
 .tracer was purified in a Sephadex G-25 fine column
which had been equilibrated and eluted with 0.1 M acetic
 .acid containing bovine serum albumin 0.1% wrv . The
specific activity of the purified labelled peptide was f600
Cirmmol.
Frontoparietal cortical membranes were prepared as
w xpreviously described by Reubi et al. 38 . The frontopari-
etal cortex was homogenized in 10 mM HEPES-KOH
 .buffer pH 7.5 with a Brinkmann polytron homogenizer
 .setting 5, 15 s . The homogenate was spun at 600=g for
5 min at 48C and the supernatant centrifuged at 48 000=g
for 30 min at 48C. The resulting pellet was suspended in
 .10 mM HEPES-KOH pH 7.5 and centrifuged as before.
The new pellet was then re-suspended in 50 mM Tris–HCl
 .buffer pH 7.5 . Samples were stored at y708C until
assay. Proteins were assayed by the method of Lowry et al.
w x29 , with bovine serum albumin as a standard. Specific SS
binding was measured according to the modified method
w x of Czernik and Petrack 8 . The membranes 0.15 mg
.proteinrml were incubated in 250 ml of a medium con-
 .taining 50 mM Tris–HCl buffer pH 7.5 , 5 mM MgCl ,2
 .0.2% wrv bovine serum albumin and 0.1 mgrml baci-
w125 x 11tracin with 250 pM I Tyr -SS either in the absence or
presence of 0.01–10 nM unlabelled SS. After a 60-min
incubation at 308C, the free radioligand was separated
from the bound radioligand by centrifugation at 12 000=g
 .Beckman microcentrifuge for 1.5 min and the resultant
pellet was counted in a Beckman g counter. Non-specific
binding, i.e. binding occurring in the presence of a high
 y7 .concentration 10 M of unlabelled SS, represented
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Table 1
Effects of fluoxetine or p-chloroamphetamine on the equilibrium parame-
ters of SS binding to rat frontoparietal cortical membranes
Groups B Kmax d
Control 531"28 0.43"0.07
b .Fluoxetine 4 h 672"39 0.42"0.06
Control 534"30 0.43"0.06
a .Fluoxetine 14 days 896"50 0.39"0.05
Control 507"38 0.58"0.06
b .p-Chloroamphetamine 1 week 373"19 0.43"0.05
Control 516"36 0.57"0.02
b .p-Chloroamphetamine 3 weeks 422"17 0.52"0.02
Binding parameters were calculated from Scatchard plots by linear regres-
sion. Units for K are nM and units for B are fmol of SS boundrmgd max
protein. The results are presented as the mean"S.E.M. of five separate
experiments, each performed in duplicate. Statistical comparison vs.
control: a P -0.001, b P -0.05.
f20% of the binding observed in the absence of native
peptide and was subtracted from the total bound radioac-
tivity in order to obtain the corresponding specific binding.
w125 x 11The inactivation of I Tyr -SS in the incubation medium
after exposure to membranes was studied by observing the
w xability of the peptide to re-bind to fresh membranes 1 .
2.5. AC assay
w xAC activity was measured as previously reported 19
with minor modifications. Briefly, rat frontoparietal corti-
 .cal membranes 0.06 mgrml were incubated with 1.5 mM
ATP, 5 mM MgSO , 10 mM GTP and an ATP-regener-4
ating system 7.5 mgrml creatine phosphate and 1 mgrml
.creatine kinase , 1 mM 3-isobutyl-1-methylxanthine, 0.1
mM phenylmethylsulphonyl fluoride, 1 mgrml bacitracin,
 y4 y51 mM EDTA and test substances 10 M SS or 10 M
. FK in 0.1 ml of 0.025 M triethanolaminerHCl buffer pH
.7.4 . After a 15-min incubation at 308C, the reaction was
stopped by heating the mixture for 3 min. After refrigera-
tion, 0.2 ml of an alumina slurry 0.75 grml in tri-
.ethanolaminerHCl buffer, pH 7.4 was added and the
suspension centrifuged. The supernatant was taken to assay
Fig. 1. Effect of acute and chronic fluoxetine administration 10 mgrkg
.i.p. on SS binding to rat frontoparietal cortical membranes. Left panel:
w125 x 11competitive inhibition of specific I Tyr -SS binding by unlabelled SS
 .to frontoparietal cortical membranes. Membranes 0.15 mg proteinrml
w125 x 11were incubated for 60 min at 308C in the presence of 250 pM I Tyr -
SS and increasing concentrations of native peptide. Points correspond to
 .  .values for the animals in the control group pool v and acute ‘ and
 .chronic I fluoxetine-treated rats. In the control group, the results
express the mean value of a pool of the control groups since B andmax
K values of the controls were not affected by the vehicle. Each point isd
the mean"S.E.M. of five separate experiments, each performed in
duplicate. Right panel: Scatchard analysis of the binding data.
X X  .cyclic adenosine 3 ,5 -monophosphate cAMP by the
w xmethod of Gilman 15 .
2.6. Data analysis
w xThe computer program LIGAND 32 was used to
analyze the binding data. The use of this program enabled
models of receptors which best fit a given set of binding
data to be selected. The same program was also used to
w xpresent data in the form of Scatchard plots 45 and to
 .compute values for receptor affinity K and densityd
 .B that best fit the sets of binding data for each rat.max
Statistical comparisons of all the data were carried out
 .with one-way analysis of variance ANOVA and the
Student-Newman-Keuls test. Means among groups were
considered significantly different when the P values were
Table 2
 y4 .  y5 .  .  .Effect of SS 10 M and FK 10 M on AC activity pmol cAMPrminrmg protein in frontoparietal cortical membranes from control ns10 ,
 .  .  .  .fluoxetine 4 h ns5 - and fluoxetine 14 days ns5 -treated rats
4 h 14 days
Control Fluoxetine Control Fluoxetine
Basal activity 168"15 170"17 172"12 166"15
y4q10 M SS 109"12 110"10 108"15 106"15
y5q10 M FK 480"20 486"26 489"23 474"22
y4 y510 M SSq10 M FK 355"30 403"20 347"24 398"23
a a% SS inhibition of FK stimulation 26"2 17"3 29"5 16"2
Experiments were performed as described in Materials and methods. Values represent the mean"S.E.M. of the determinations performed. Statistical
comparison vs. control: a P-0.05.
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Table 3
 .Effect of p-chloroamphetamine on the 5-hydroxytryptamine serotonin
levels in the rat frontoparietal cortex at 1 and 3 weeks after its administra-
tion
5-Hydroxytryptamine
1 week 3 weeks
Frontoparietal cortex
Control 412"13 421"13
a ap-Chloroamphetamine 251"7 184"7
Data are mean"S.E.M. of 5 rats in each group. Values are ng of
5-hydroxytryptaminerg wet tissue weight. a P -0.001 compared to con-
trol.
-0.05. Each individual experiment was performed in
duplicate.
3. Results
The acute and chronic administration of fluoxetine in-
w125 x 11creased I Tyr -SS binding to rat frontoparietal cortical
membranes as compared with controls. This increase was
due to a rise in the maximal number of SS receptors as
revealed by Scatchard plots of the binding data, without
 .any change in the binding affinity Table 1, Fig. 1 .
To assess the functional consequences of the changes in
SS binding, experiments were designed to examine the
effect of SS on FK-stimulated AC activity in control rats
and rats acutely treated with fluoxetine. No significant
differences were seen for either the basal or FK-stimulated
AC activities between the control and fluoxetine-treated
 .rats Table 2 . As previously observed, SS inhibited FK-
stimulated AC activity. When rats were treated with fluox-
etine acutely or chronically, the effect of SS on FK-stimu-
lated AC activity was markedly decreased in frontoparietal
 .cortical membranes Table 2 .
Further experiments explored the effect of fluoxetine on
G -proteins in rat frontoparietal cortical membranes byi
 .determining the ability of low Gpp NH p concentrations to
inhibit FK-stimulated AC activity. The inhibitory effect of
 .Gpp NH p on FK-stimulated AC activity was markedly
X   . .Fig. 2. Dose–effect curves for 5 guanylylimidodiphosphate Gpp NH p
on FK-stimulated AC activity in rat frontoparietal cortical membranes
 .  .  .from controls v and acute ‘ and chronic I fluoxetine-treated rats.
The results express the values of a pool of the control groups since no
 .differences among them were found. The effect of Gpp NH p on AC
activity was studied in the presence of 3=10y6 M FK and the indicated
 .concentrations of Gpp NH p. Data are expressed as a percentage of
 .  .FK-stimulated AC activity in the absence of Gpp NH p 100% . The
results are the mean"S.E.M. of three separate determinations, each
performed in duplicate. Statistical comparison vs. control: ) P -0.05,
) ) P -0.01.
decreased in frontoparietal cortical membranes from rats
 .acutely or chronically treated with fluoxetine Fig. 2 .
With the aim of determining the effect of decreased
serotonergic neurotransmission on the SS receptor–AC
system, a group of rats were treated with p-chloro-
amphetamine, which depletes 5-hydroxytryptamine levels
 .in the rat brain Table 3 , leading to a lasting reduction of
5-hydroxytryptamine innervation in the neocortex and other
forebrain structures. p-Chloroamphetamine administration
leads to a decrease in the number of SS receptors in the
frontoparietal cortical membranes, with no change in the
 .binding affinity Table 1 .
No significant differences were seen for either the basal
or FK-stimulated AC activities between the control rats
and rats treated with p-chloroamphetamine. The capacity
of SS to inhibit basal and FK-stimulated AC activity in
these experimental groups is shown in Table 4. The effect
Table 4
 y4 .  y5 .  .  .Effect of SS 10 M and FK 10 M on AC activity pmol cAMPrminrmg protein in frontoparietal cortical membranes from control ns10 and
 .p-chloroamphetamine ns5 in each group -treated rats
1 week 3 weeks
Control p-Chloroamphetamine Control p-Chloroamphetamine
Basal activity 160"10 168"16 163"20 160"23
y4q10 M SS 103"21 105"14 93"15 100"11
y5q10 M FK 474"7 453"20 455"22 464"20
y5 y410 M FKq10 M SS 354"29 381"20 343"25 398"8
a a% SS inhibition of FK stimulation 25"3 15"2 24"3 14"2
Experiments were performed as described in Materials and methods. Values represent the mean"S.E.M. of the determinations performed. Statistical
comparison vs. control: a P-0.05.
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of SS on FK-stimulated AC activity was decreased in
frontoparietal cortical membranes from p-chloro-
amphetamine-treated rats as compared to control animals
 .Table 4 .
Frontoparietal cortical membranes from control and p-
chloroamphetamine-treated rats showed similar G -proteini
 .activity data not shown at 1 and 3 weeks after its
administration.
4. Discussion
In the present study, we have shown that the increase of
serotonergic transmission induced by acute or chronic
administration of fluoxetine, a selective 5-hydroxytryp-
tamine re-uptake inhibitor, leads to a rise in the number of
SS receptors, without altering their affinity, in the rat
frontoparietal cortex. However, this treatment results in a
reduction of the ability of SS to inhibit FK-stimulated AC
activity. In addition, the decrease of serotonergic transmis-
sion induced by reduction of 5-hydroxytryptamine innerva-
tion in the neocortex due to systemic p-chloroampheta-
w xmine administration 12 leads to a decrease of the number
of SS receptors and of the ability of SS to inhibit FK-
stimulated AC activity in frontoparietal cortical mem-
branes.
The binding parameters of SS receptors in the control
rats were similar to those previously reported by others
w x49 . Recently, five different SS receptor subtypes have
w xbeen cloned 20 and the tissue distribution of the messen-
ger ribonucleic acid for each subtype has been studied in
w x w125 x 11the rat 4 . The fact that this study with I Tyr -SS
shows only one type of SS receptor might be explained by
the hypothesis that this radioligand binds to all types of SS
receptors with dissociation constants that are virtually
identical and cannot be discriminated by Scatchard analy-
sis.
The increase in the number of SS receptors was ob-
served at a concentration of fluoxetine that produces a
significant increase in the extraperikaryal 5-hydroxytryp-
w xtamine concentration in the rat brain 55 , leading to an
enhanced activation of synaptic 5-hydroxytryptamine re-
w xceptors as observed in functional studies 47 .
5-hydroxytryptamine is known to bind and activate
receptors coupled to different signaling pathways. In the
rat cerebral cortex, both 5-hydroxytryptamine 5-HT and1
w x5-HT receptors have been described 11,21 . Several 5-2
hydroxytryptamine receptor subtypes, such as 5-HT , 5-1A
HT , 5-HT and 5-HT , are negatively coupled to AC,1B 1D 1E
whereas 5-HT , 5-HT and 5-HT are positively cou-2A 2B 2C
w xpled to phospholipase C 21 . On the other hand, it has
been shown that cAMP analogs or agents whose action
increases cell cAMP levels modulate SS binding by de-
creasing the maximal binding capacity of the receptors
w x31 . Since activation of the 5-hydroxytryptamine receptors
5-HT , 5-HT , 5-HT and 5-HT exerts a negative1A 1B 1D 1E
control on AC, it seems likely that the increase in the
number of SS receptors following acute and chronic fluox-
etine administration is the result, at least in part, of a
decreased activation of a phosphorylation pathway via the
 .cAMP-dependent protein kinase A PKA . Recently, we
found that the administration of a single dose of 5-
hydroxytryptamine was accompanied by an increase in the
w xnumber of SS receptors in the rat frontoparietal cortex 33 .
It has been shown that chronic treatment with similar
doses of fluoxetine induces an increased serotonergic func-
w xtion 43 . In vitro binding and quantitative autoradio-
graphic studies have shown that neither 5-HT , 5-HT ,1A 1B
5-HT nor 5-HT receptor-binding sites in various brain2A 3
w xareas are affected by chronic fluoxetine treatment 27 .
However, other authors have shown that chronic fluoxetine
treatment up-regulates 5-HT uptake sites and 5-HT recep-2
w xtors in rat brain 5 .
The changes in SS binding were not due to a direct
effect of 5-hydroxytryptamine on SS receptors since no
change in tracer binding was detected following incubation
of fresh frontoparietal cortical membranes with fluoxetine
w xor 5-hydroxytryptamine 33 . This is consistent with the
absence of any apparent structural analogy between these
molecules.
Daily administration of fluoxetine to rats did not change
radioligand binding to a -, or a -adrenergic, muscarinic1 2
w xcholinergic, H -histaminergic or opiate receptors 56 , sug-1
gesting that these neurotransmitter systems are not impli-
cated in the increase of the number of SS receptors found
following long-term fluoxetine administration.
Several studies suggest that a central serotonergic
mechanism plays a role in the regulation of SS-containing
neurons. However, to date, these studies have frequently
seemed contradictory. There are studies suggesting that
w x5-hydroxytryptamine may inhibit SS release 9 . This
mechanism could be involved in the increase of the num-
ber of SS receptors observed following acute and chronic
w xfluoxetine administration. In contrast, other authors 2,24
have postulated that augmentation of serotonergic activity
probably stimulates SS release in the cerebral cortex and
hippocampus. If this is so, the increase of serotonergic
neurotransmission induced by fluoxetine administration
could lead to a rise of SS levels in the synaptic cleft that,
together with the elevation of the number of SS receptors,
would increase somatostatinergic neurotransmission. In ad-
dition, 5-hydroxytryptamine was found to have no influ-
ence on SS release either from cultured cerebral cortical
w x w xcells 39 or from hypothalamic tissues 30 .
The effects of p-chloroamphetamine are characterized
by an acute release of 5-hydroxytryptamine followed by a
marked decrease in forebrain levels of this neurotrans-
mitter; many 5-hydroxytryptamine axon terminals undergo
subsequent degeneration, leading to a lasting reduction of
5-hydroxytryptamine innervation in the neocortex and other
w xforebrain structures 12 . A possible mechanism for the
decrease of the number of SS receptors after p-chloro-
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amphetamine administration is that it is secondary to a
decreased serotonergic activity; the serotonergic lesion
could be removing serotonergic input to somatostatinergic
neurons, altering SS release and thereby changing the
number of post-synaptic SS receptors. Alternatively, it is
possible that some SS receptors are localized pre-synapti-
cally on serotonergic axons and, therefore, the degradation
of these axons due to p-chloroamphetamine administration
would be responsible for the observed decrease of SS
binding.
Basal cAMP levels were unaffected by p-chloro-
amphetamine and fluoxetine which is in agreement with
w xprevious studies 51 . Basal and FK-stimulated AC activity
was inhibited by SS in all the experimental groups studied
w xwhich is in agreement with the literature 3,35,46 . A very
 y4 .high concentration of SS 10 M was required to pro-
duce this inhibition although the same concentration was
w x w xused by Schettini et al. 46 , Bergstrom et al. 3 , Garlind et¨
w x w xal. 14 and Nagao et al. 35 in their studies on SS-media-
ted AC activity in rat and human brain. However and
despite this high concentration, several lines of evidence
suggest that the effect of SS is receptor-mediated and is
not due to a non-specific inhibitory effect. In this regard,
the GTP dependency of the inhibitory effect suggests the
involvement of a G-protein in this response. This finding is
consistent with binding studies on post-mortem human and
rat brain tissues which have shown that the binding of SS
to its recognition site is affected by GTP in a manner
consistent with the involvement of a G-protein. In addi-
w x w xtion, Nagao et al. 35 and Shettini et al. 46 have shown
that SS-reduced cAMP formation in the rat brain occurs
via a G-protein coupled to AC. Overall results, plus the
 .lack of a SS 1 mM inhibitory effect on basal adenylate
cyclase activity in primary cultures of mouse embryonic
w xglial cells reported by Chneiweiss et al. 6 would argue
against a non-specific inhibitory effect of the neuropeptide.
The ability of SS to inhibit FK-stimulated AC activity is
significantly attenuated in frontoparietal cortical mem-
branes from fluoxetine or p-chloroamphetamine-treated
rats as compared with their controls. We have assessed
possible involvement of AC catalytic subunit and the
functional activity of G-protein coupling in this enzymatic
response to SS in both treatments. FK-stimulated AC
activity was not affected by fluoxetine or p-chloro-
amphetamine administration which allows us to exclude
the possibility that both substances affect the functioning
of the AC catalytic subunit. We have also examined the
 .response of AC to the GTP analogue Gpp NH p as an
index of the functional activity of the coupling G-protein.
 .The inhibitory effect of Gpp NH p on FK-stimulated AC
activity was markedly decreased in frontoparietal cortical
membranes from rats acutely and chronically treated with
fluoxetine which suggests that there is a less functional
G -protein in these membranes that would explain thei
decreased inhibition of AC by SS after acute or chronic
fluoxetine administration.
The results obtained following acute and chronic fluox-
etine administration are consistent with data of Rovescalli
w xet al. 41 who found that in vitro exposure of cortical
slices to 5-hydroxytryptamine results in reduced SS inhibi-
tion of FK-stimulated AC activity. In addition, Rovescalli
w xet al. 41 confirmed that 5-hydroxytryptamine may trigger
 .protein kinase C PKC activation which seems to be a
 .prerequisite for sensitizing AC towards Gpp NH p. It has
been shown that PKC, by phosphorylating the G -proteinsi
w x w x44 , can suppress hormonal inhibition of AC 25 . There-
fore, the fact that the ability of SS to inhibit FK-stimulated
AC activity is reduced following acute fluoxetine adminis-
tration supports the hypothesis that 5-hydroxytryptamine
might functionally inactivate G -proteins through PKC-i
mediated phosphorylation. Recently, the findings of Lesch
w xet al. 28 indicate a direct effect of chronic antidepressant
administration on steady-state concentrations of G-protein
subunits, decreasing the G a-protein in several brain re-i
gions. This G a-protein mediates inhibition of AC by SSi
receptors.
The present results suggest that under normal circum-
stances some SS receptors are under a tonic stimulatory
control through the serotonergic system. Both the seroton-
ergic and somatostatinergic systems have been implicated
in depression as well as in other central nervous system
w xdisorders 23,42 . These results indicate the existence of
serotonergic and somatostatinergic interactions in the rat
frontoparietal cortex and suggest that the SS receptor–AC
system is implicated in the mechanism of action of the
antidepressant drug fluoxetine. Therefore, it is tempting to
speculate that the somatostatinergic system may play a role
in the pathophysiology of depression.
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